Neurology
Addressing the critical gap in agitation management through non-sedating V1a antagonism and phenotype-selective development. See Disclaimer below * Alzheimer’s Disease (AD) affects an estimated 6.7 million Americans, with agitation and aggression emerging in approximately 40-50% of patients during the disease course. This translates to a Total Addressable Market (TAM)
Neurology
AC Immune’s Phase 2 interim analysis delivers a rare trifecta in neurodegeneration: 100% target engagement, biomarker stabilization, and clinical efficacy signals. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * In a therapeutic
Neurology
Kallyope's first-in-class oral antagonist meets co-primary endpoints, offering a distinct non-CGRP mechanism for refractory patients. * These analyses reflect my personal opinions and may include input from multiple sources. They are for informational purposes only and do not constitute professional advice. * Clinical Impact Analysis The landscape of acute migraine
News
Capricor Therapeutics’ pivotal data addresses previous regulatory hurdles, positioning the cell therapy as a first-in-class treatment for Duchenne cardiomyopathy.
News
New biomarker data from the RewinD-LB extension confirms that optimized drug delivery reverses neuroinflammation, reviving the asset's commercial potential against a backdrop of unmet need.